BioGenex, a global provider of customer-centric molecular pathology solutions, complete walk-away kits and automation for diagnosis, prognosis and therapy selection for cancer, has completed a phase I construction of the Center of Excellence in Hyderabad, India.
The 100,000-sqft Center of Excellence is located on a 20-acre site in the Special Economic Zone (SEZ) of Hyderabad, a large business hub located right off the Outer Ring Road. This centralized location and proximity to RGI Airport allows for more efficient international business transactions.
The new township will have over 40,000 employees by the end of 2016. TCS (Tata Consultancy) and TATA Advance Systems are among other major institutions building large facilities in the area. BioGenex will use this facility for design and development of multiple new molecular pathology systems and for manufacturing of Xmatrx family instruments. As part of the phased transition, BioGenex's instrument manufacturing, supply chain, stock rooms, R&D, engineering and QA departments have already moved into the facility.
Though the facility aims to provide support to both domestic and international markets, global exports will be the key focus area. To help meet the demands of the growing business, the new facility houses complete manufacturing capability for BioGenex's suite of molecular pathology work systems along with the supporting reagents and consumables. The facility also allows for expanded training for our international and domestic distributors and customers.
"This is an important move for BioGenex to ensure that we understand our customer's requirements and tailor our products to meet their needs. Our location in Hyderabad establishes a regional presence with global support capabilities to provide timely product delivery, enhance technical support, complete laboratory set-up for training and to facilitate new product development and launch," said Dr. Krishan Kalra, CEO of BioGenex.
BioGenex is committed to providing products and instruments for Molecular Pathology clinical and research. This is one of the steps we are taking to fulfill that commitment.